Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Short Interest Up 79.8% in June

Posted by Stanley Muller on Jul 4th, 2026

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR – Get Free Report) saw a large increase in short interest in June. As of June 15th, there was short interest totaling 1,130,432 shares, an increase of 79.8% from the May 31st total of 628,655 shares. Currently, 2.9% of the company’s stock are short sold. Based on an average trading volume of 279,068 shares, the days-to-cover ratio is presently 4.1 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Get Our Latest Report on Coeptis Therapeutics

Hedge Funds Weigh In On Coeptis Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Marshall Wace LLP purchased a new position in Coeptis Therapeutics in the fourth quarter worth about $259,000. State Street Corp lifted its stake in shares of Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares during the last quarter. Steward Partners Investment Advisory LLC grew its holdings in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares during the last quarter. Finally, Yorkville Advisors Global LP bought a new stake in shares of Coeptis Therapeutics during the third quarter valued at approximately $140,000. Institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Price Performance

ZSQR stock opened at $10.99 on Friday. Coeptis Therapeutics has a twelve month low of $7.41 and a twelve month high of $21.41. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. The firm has a market cap of $565.22 million, a PE ratio of -4.36 and a beta of -0.25. The business has a 50 day moving average of $12.01 and a 200 day moving average of $12.61.

Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The company had revenue of $0.11 million during the quarter.

About Coeptis Therapeutics

(Get Free Report)

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.